To overcome NK cell suppression, in a systemic delivery setting, a combination of a STING agonist with a PI3Kγ inhibitor reduced the number of Bregs in PDAC while increasing the number of myeloid cells, thereby mediating tumor control.[115] This highlights the potential of Breg inhibitors together with CAR‐NK cell therapy (Figure 4). This evidence concerns the gene STING1 and neoplasm.